Search results
AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock | The Motley Fool
The Motley Fool· 3 days agoAs two of the world's largest and most prolific drugmakers, Pfizer (PFE -1.70%) and AstraZeneca (AZN...
AstraZeneca-Daiichi's Enhertu follow-up Dato-DXd unable to prove overall survival benefit in phase 3
FierceBiotech· 4 days agoDaiichi Sankyo and antibody-drug conjugate (ADC) partner AstraZeneca have already filed their...
AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock? | The Motley Fool
The Motley Fool· 3 days agoAstraZeneca (AZN -0.70%) is embarking on a fresh business plan that will see it grow significantly...
AstraZeneca stock upgraded by Goldman, 27% upside seen By Investing.com
Investing.com· 2 days agoOn Thursday, Goldman Sachs (NYSE:GS) initiated coverage on AstraZeneca (NASDAQ:AZN:LN) (NASDAQ: AZN)...
AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?
Motley Fool via Yahoo Finance· 3 days agoAstraZeneca (NASDAQ: AZN) is embarking on a fresh business plan that will see it grow significantly...
New antibiotic based on AstraZeneca drugs kills off deadly bacteria, spares the good guys
FierceBiotech· 22 hours agoA new antibiotic based on drugs developed by AstraZeneca can kill off dangerous bacteria that cause...
Compugen hits milestone with AstraZeneca cancer trial By Investing.com
Investing.com· 1 day agoThe trial is a crucial step in evaluating the drug as a first-line treatment for a specific type of...
AstraZeneca shares target raised by Argus on new drug approvals By Investing.com
Investing.com· 2 days agoOn Thursday, AstraZeneca PLC (NASDAQ:LON:AZN) shares received an updated price target from a market...
US FDA approves Amgen's biosimilar to AstraZeneca's rare blood disorder treatment
Reuters via AOL· 3 days agoAmgen's drug will be marketed under the name Bkemv. Biosimilars are close copies of complex...
AstraZeneca PLC (NASDAQ:AZN) Stock Holdings Lifted by Hsbc Holdings PLC
ETF DAILY NEWS· 2 days agoHsbc Holdings PLC raised its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 13.7% during the fourth quarter, according to its most recent Form 13F filing with the ...